These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 27918726)
1. MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future. Jhaveri K J Clin Oncol; 2017 Jan; 35(2):127-130. PubMed ID: 27918726 [No Abstract] [Full Text] [Related]
2. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224 [TBL] [Abstract][Full Text] [Related]
3. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472 [TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Bighin C; Pronzato P; Del Mastro L Future Oncol; 2013 Jul; 9(7):955-7. PubMed ID: 23837759 [TBL] [Abstract][Full Text] [Related]
5. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Patel KC; Hageman K; Cooper MR Am J Health Syst Pharm; 2014 Apr; 71(7):537-48. PubMed ID: 24644113 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. Isakoff SJ; Baselga J J Clin Oncol; 2011 Feb; 29(4):351-4. PubMed ID: 21172881 [No Abstract] [Full Text] [Related]
8. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Baron JM; Boster BL; Barnett CM J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654 [TBL] [Abstract][Full Text] [Related]
9. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. van Boxtel W; Boon E; Weijs WLJ; van den Hoogen FJA; Flucke UE; van Herpen CML Oral Oncol; 2017 Sep; 72():198-200. PubMed ID: 28673692 [No Abstract] [Full Text] [Related]
10. Trastuzumab emtansine in HER2-positive metastatic breast cancer. Montemurro F Lancet Oncol; 2017 Jun; 18(6):696-697. PubMed ID: 28526537 [No Abstract] [Full Text] [Related]
11. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071 [TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Van den Mooter T; Teuwen LA; Rutten A; Dirix L Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453 [TBL] [Abstract][Full Text] [Related]
13. A systematic review of dual targeting in HER2-positive breast cancer. Kümler I; Tuxen MK; Nielsen DL Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156 [TBL] [Abstract][Full Text] [Related]
15. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681 [TBL] [Abstract][Full Text] [Related]
16. HER2 testing in patients with breast cancer. Dixon JM; Wilson V; Verrill M; Symmans WF BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887 [No Abstract] [Full Text] [Related]
17. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Mathew J; Perez EA Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845 [TBL] [Abstract][Full Text] [Related]
18. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217 [No Abstract] [Full Text] [Related]
19. HER2-positive breast cancer: a new piece of the puzzle. Gnant M; Bartsch R; Steger GG Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817 [No Abstract] [Full Text] [Related]
20. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. Janjigian YY; Braghiroli MI Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]